REMINDER: Our user survey closes on Friday, please submit your responses here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,780.50
Bid: 1,778.50
Ask: 1,779.00
Change: 7.00 (0.39%)
Spread: 0.50 (0.028%)
Open: 1,780.00
High: 1,786.50
Low: 1,771.50
Prev. Close: 1,773.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

MARKET COMMENT: FTSE 100 Led Higher By Mining Constituents

Mon, 02nd Jun 2014 16:33

LONDON (Alliance News) - The FTSE 100 started the month on the front foot Monday, closing higher, after a gauge of China's factory activity rose to a five-month high in May, suggesting the world's second-largest economy is stabilising after a subdued start to the year.

China's official manufacturing purchasing managers' index posted its third straight month of improvement in May, rising to 50.8 from 50.4 in April.

"Despite all of the concerns regarding Chinese growth this year, this number has not crossed the line into contraction territory once which may suggest the slowdown hasn't been as bad as first thought," said Craig Erlam, a market analyst at Alpari. "Alternatively, it may just highlight the fact that the survey predominantly covers the larger firms that are supported by the Chinese government, rather than the overall sector right now," he added.

"Whilst this does not completely dispel concerns over the Chinese economy, it is a step in the right direction," said Richard Perry, a market analyst at Hantec Markets.

Anglo American, closing up 2.3%, Rio Tinto, closing up 2.1%, Glencore, closing up 1.4%, and BHP Billiton, closing up 1%, were all big winners in the FTSE 100, while the FTSE 350 mining sector index ended the day up 1.6%.

Overall, the FTSE 100 closed up 0.3% at 6,864.1, the FTSE 250 closed up 0.5% at 16,084.4, while the AIM All-Share index closed down 0.4% at 812.5.

In Europe, stocks closed mixed.

The manufacturing industry across Europe performed slightly worse in May than first thought, as the final Markit service sector PMI's were broadly revised lower. The only major economy to have its economy revised higher was France, but with a reading of 49.6, the French manufacturing sector has been confirmed to be contracting after the initial print of 49.3.

"The disappointing data paints a picture of a sector struggling to generate any sort of traction in recovery," said Markit senior economist Jack Kennedy.

In Germany, the manufacturing sector PMI was a more healthy 52.3 in May, although still lower than the flash estimate of 52.9, and a drop from April's 54.1. The eurozone wide print was also revised slightly lower to 52.2, from the flash estimate of 52.5.

"On balance, newsflow from the Eurozone has proven increasingly disappointing relative to economists’ forecasts over recent months," said DailyFX currency strategist Ilya Spivak. "Such outcomes may amplify speculation about an expansion of European Central Bank stimulus at this week’s policy meeting," he added.

Shortly after the disappointing PMI data, the preliminary reading of German consumer price inflation fell short of economists' forecasts. Europe's largest economy's CPI fell to 0.9% year-on-year in May, down from 1.3% in April and missing the expected rate of 1.1%.

The CAC 40 in Paris closed down 0.1%, while the DAX 30 in Frankfurt closed up 0.1%.

On Wall Street, after a strong start, stocks plummeted following a report by the Institute for Supply Management that showed an unexpected decrease in its reading on US manufacturing activity. The ISM said its manufacturing index dipped to 53.2 in May, down from 54.9 posted in April, and missing economists' estimates for an increase to 55.4.

However, they have since recovered and currently trade close to flat, after the ISM later issued a correction saying that a software error applied last month's seasonal adjustment factor to this month's data. It clarified that the index should have risen to 56.0 in May, which would have come in above the 55.4 expected by economists.

"Overall, based on the corrected survey, it appears that manufacturing activity is still gathering momentum after the winter slowdown," said Paul Ashworth, chief economist at Capital economics.

Meanwhile, the US Markit manufacturing PMI reading for May came in at 56.4, which comfortably beat the 55.4 posted in April and the 55.5 that had been expected by economists.

At the UK equity market close, the DJIA is up 0.1%, the S&P 500 is fractionally higher, while the NASDAQ Composite is down 0.2%.

At the individual UK equity level, but away from the mining sector, pharmaceutical company Shire was among the leading risers in the blue-chip index Monday, closing up 2%. Shares in the company rose after The Times reported that it had secured a USD5 billion credit facility from banks including Citigroup to finance a takeover offer for the US's NPS Pharmaceuticals. Shire is believed to have arranged the deal to buttress its takeover offer for NPS, a developer of drugs for sufferers of a debilitating bowel condition.

Smith & Nephew, closing down 1.9%, was among the index's biggest losers. The medical technology company fell sharply following an extremely strong share price run, which had seen it close the previous three session as the FTSE 100's biggest riser.

The group jumped 9.8% in three days after the Financial Times published an article last Wednesday that suggested that Stryker, a US maker of hip implants and knee replacements, was about to make an unquantified takeover bid for the company. While Stryker quickly denied the rumours, Smith & Nephew's shares still benefited from the speculation.

GlaxoSmithKline was another big loser Monday, ending the day down 0.5%.

The pharmaceutical company has signed a collaboration and licensing agreement with UK-based biotechnology company Adaptimmune Ltd for its cancer programme, a move that comes just weeks after it agreed to sell its own cancer drug business to Novartis as part of a broader asset swap.

Glaxo's deal with the biotechnology company will see the two companies develop and commercialise Adaptimmune's NY-ESO-1 cancer treatment, as well as Adaptimmune's other treatments using its T-cell receptor engineering technology. Adapitmmune said the deal would be worth a potential USD350 million to it over the next seven years.

Still, Glaxo ended the day lower after it said on Sunday that a late stage study of two potential early breast cancer treatments used in combination, lapatinib and trastuzumab, suggested there was no improvement in disease free survival compared to using just trastuzumab.

In the FTSE 250, St Modwen Properties was a big winner, closing up 2.5%. The property company's shares rose after it said that it still expects to report pretax profit for the first half of its financial year significantly up on the year-earlier period, after it continued to perform "strongly" over the past two months.

It said it expects its asset management and added value activities to be reflected positively in half-year valuations, while initial indications point to a rise in market valuations for the first-half of the year compared with November 2013, reflecting improvements in the residential and commercial property markets across the UK.

AIM All-Share listed Bglobal ended the day up 60%. Shares in the company rocketed after it said that it had agreed to sell its Utiligroup Ltd subsidiary for GBP16.1 million in cash to private equity company NorthEdge Capital LLP, and that it plans to return money to shareholders and de-list from AIM once the deal completes.

Bglobal said it expects to have cash balances of GBP16.8 million after the deal completes, and is already talking with its advisors about the most effective way of returning this money to its shareholders. However, it said the deal will have to be approved by its shareholders.

In the forex market, the pound edged lower against its major rivals Monday morning following the release of some weaker-than-expected UK macro economic data, before reclaiming its losses as the day wore on.

Lending data released by the Bank of England shortly after the UK equity market open showed that mortgage approvals dropped to a nine-month low in April, with 62,918 loans approved, down from 66,563 in March and missing economist expectations for 64,750. Mortgage approvals have declined every month this year so far, with the Bank of England unsure as to the exact reason, although there are suggestions that banks began to rein in lending early ahead of the stricter lending rules introduced recently as part of the Mortgage Market Review.

While there are calls from some to the BoE to act to stem the rising UK house prices, they may be less likely to introduce any new measure in light of the already falling mortgage approvals, analysts say.

At the same time, the BoE revealed that the amount borrowed by individuals in the UK dropped to GBP0.67 billion in April from GBP1.03 billion in March, missing economists expectations of a more modest decrease to GBP0.8 billion.

Meanwhile, the UK Markit manufacturing PMI came in as expected at 57.0 in May, slightly lower than the 57.3 recorded in April but still indicating strong growth in the sector.

The euro experienced a similar day Monday. The single currency ticked lower in early trading following the mixed European PMI data, before recovering as the day wore on.

At the UK equity market close, the pound trades at USD1.6752, EUR1.2312, CHF1.5048, and JPY171.380, while the euro trades at USD1.3604, CHF1.2218, and JPY139.160.

In the data calendar Tuesday, Chinese non-manufacturing purchasing managers' index information is released at 0200 BST, with the latest reading of Chinese HSBC manufacturing PMI released at 0245 BST.

UK Nationwide house price data are published at 0700 BST, shortly before the Bank of England credit conditions survey and UK construction PMI information at 0930 BST. Consumer price inflation and unemployment data for the euro zone is released at 1000 BST.

In the US, the ISM New York index is released at 1445 BST, with factory orders data due at 1500 BST.

In the corporate calendar, blue-chip Wolseley releases a trading update, while FTSE 250-listed LondonMetric Property and Pennon Group release full-year results.


By James Kemp; jameskemp@alliancenews.com; @jamespkemp

Copyright 2014 Alliance News Limited. All Rights Reserved.

More News
18 Dec 2023 10:07

GSK's dostarlimab trial in endometrial cancer meets primary endpoint

(Alliance News) - GSK PLC on Monday said a trial of dostarlimab in combination with niraparib for treating endometrial cancer has met its primary endpoint.

Read more
18 Dec 2023 07:55

LONDON BRIEFING: Games Workshop seals Amazon deal for Warhammer 40,000

(Alliance News) - Stocks in London were set to retreat slightly on Monday, in line with equity markets in Asia, at the start of the last week before the Christmas holidays.

Read more
18 Dec 2023 07:18

GSK sees success in Jemperli endometrial cancer trial

(Sharecast News) - GSK released positive headline results from the planned analysis of its trial of Jemperli in endometrial cancer on Monday.

Read more
17 Dec 2023 15:16

PRESS: GSK looks for deals in China as rebuilds relationship

(Alliance News) - The Financial Times on Sunday reported that GSK PLC is looking for some new deals in China.

Read more
15 Dec 2023 17:08

European shares end fifth week higher on rate-cut optimism

Barclays sees first ECB rate cut in April

*

Read more
15 Dec 2023 16:51

LONDON MARKET CLOSE: FTSE 100 underperforms as post-Fed rally cools

(Alliance News) - London's FTSE 100 ended lower on Friday, with profit-taking and some hawkish words from a US policymaker keeping equities in check at the end of a largely positive week for stocks.

Read more
15 Dec 2023 16:29

PRESS: GSK, Astra and AbbVie in US scrutiny over patents - Bloomberg

(Alliance News) - A US senator has accused AstraZeneca PLC, GSK PLC, AbbVie Inc and other drugmakers of "abusing" the patent system to send prices higher, Bloomberg reported on Thursday.

Read more
12 Dec 2023 10:08

AstraZeneca buys respiratory vaccine developer Icosavax in $1.1 bln deal

Dec 12 (Reuters) - AstraZeneca said on Tuesday it had agreed to buy respiratory syncytial virus (RSV) vaccine developer Icosavax in a deal valued at up to $1.1 billion.

Read more
12 Dec 2023 08:22

TOP NEWS: Japan accepts GSK's filing for respiratory disease vaccine

(Alliance News) - GSK PLC on Tuesday said Japan's Ministry of Health, Labour & Welfare has accepted its regulatory application for the extension of its respiratory syncytial virus vaccine, Arexvy, for adults aged 50-59.

Read more
12 Dec 2023 07:39

LONDON BRIEFING: UK unemployment unchanged at 4.2%; eyes on US CPI

(Alliance News) - Stocks in London are called to open higher, as investors digest the latest UK unemployment data, before turning their heads to US inflation.

Read more
12 Dec 2023 07:24

GSK seeks to extend RSV vaccine approval in Japan

(Sharecast News) - GSK announced on Tuesday that Japan's Ministry of Health, Labour and Welfare (MHLW) has accepted its regulatory application for the extension of the indication of its RSV vaccine to include adults aged 50- to 59 at an increased risk of contracting the disease.

Read more
11 Dec 2023 08:28

GSK drug gets EU marketing backing for form of endometrial cancer

(Alliance News) - GSK PLC on Monday said it won EU backing for its Jemperli drug in tandem with chemotherapy to treat a form of endometrial cancer.

Read more
11 Dec 2023 07:41

LONDON BRIEFING: GSK drug gets EU endorsement; Begbies backs outlook

(Alliance News) - London's FTSE 100 is called to open a touch lower on Monday, kicking off the week with some slight trepidation after Friday's hotter-than-expected US jobs report which offered the dollar some respite.

Read more
11 Dec 2023 07:23

GSK endometrial cancer treatment gets Europe authorisation

(Sharecast News) - GSK announced on Monday that the European Commission has granted marketing authorisation for 'Jemperli', or dostarlimab, in combination with chemotherapy for certain endometrial cancers.

Read more
7 Dec 2023 12:54

THG backer Kelso pushes for demerger to trim "inherent" valuation gap

(Alliance News) - THG PLC investor Kelso Group Holdings PLC on Thursday reiterated its call for a demerger, which the shareholder believes will help close the "disparity" between the e-commerce firm's share price and its true value.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.